In order to implement our new strategic plan, and to realign the organization after the retirement of Dr. Brad Popovich, I am pleased to announce that Dr. Gabe Kalmar is appointed the Vice President, Entrepreneurship and Commercialization, and Dr. Rachael Ritchie is appointed Director, International Partnerships, both reporting to me.
Gabe Kalmar, currently the Vice President, Sector Development, has significant experience in the private sector. From 1996 to 2002, he held senior management positions with Kinetek Pharmaceuticals Inc., a privately held Vancouver-based biopharmaceutical company that was acquired by QLT in March, 2004. Gabe has undertaken strategic consulting activities with several early stage pharmaceutical companies which included overseeing operations, implementing technology development and providing merger and acquisition planning. In addition, he has also developed Genome BC's current pilot projects in entrepreneurship and commercialization, which are now being expanded into regular Genome BC's programs.
Gabe will also continue as Vice President, Sector Development until a replacement is found through a national search, now underway.
Rachael Ritchie, currently the Director, Business Development, has wide experience in international research in Oxford and Boston and over 11 years with the New Brunswick Research and Productivity Council. More recently, Rachael worked as a Policy Analyst in the OECD’s Science Technology Policy Division in Paris, working with member states and other stakeholders to develop analytical frameworks to inform science and technology policy. This work built on the widely-acclaimed OECD study entitled The Bioeconomy 2030. She is Chair of the International Advisory Group for the European Union ERA-NET in marine biotechnology. Her experience spans the health, natural resource (aquaculture, fisheries and food) and biotech sectors.
Please join me in welcoming Gabe and Rachael to their new positions.
Dr. Alan E. Winter
President & CEO